Skip to main content
logo
Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
134.79
+0.04 (0.03%)
Aug 21, 2026, 9:14 AM EDT - Market open

Apogee Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-294.37-255.84-182.15-83.99-43.4
Depreciation & Amortization
1.631.420.19--
Loss (Gain) From Sale of Investments
-6.65-7.5-12.24-3.07-
Stock-Based Compensation
57.6346.2823.336.12.34
Other Operating Activities
5.463.681.690.0912.44
Change in Accounts Payable
-2.60.15-1.071.610.46
Change in Other Net Operating Assets
-5.03-15.63-0.934.4910.25
Operating Cash Flow
-243.89-227.45-171.17-74.76-17.92
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
-0.06-5.15-1.15-0.17-
Investment in Securities
-687.84-174.43-299.31-273.74-
Investing Cash Flow
-687.89-179.57-300.46-273.91-

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Issuance of Common Stock
815.12396.49495.11315.39-
Other Financing Activities
97.75----0.75
Financing Cash Flow
912.87396.49495.11315.39183.62

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
-18.92-10.5323.47-33.28165.7

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-243.96-232.6-172.33-74.93-17.92
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-3.60-3.83-3.12-3.00-7.28
Levered Free Cash Flow
-145.62-138.98-113.42-45.5-
Unlevered Free Cash Flow
-144.64-138.98-113.42-45.5-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Change in Working Capital
-7.62-15.48-26.1110.71
SEC Filings: 10-K · 10-Q